tissue damage News
-
Holostem at the second asset talk organised by Clust-ER Health
On Thursday 3 June, the second event dedicated to the exploration of the assets identified during 2020 in the in-depth analysis of the potential and prospective attractiveness carried out on the health and wellness sector in Emilia-Romagna will be held. The theme of this meeting, which will start at 5 p.m., is advanced therapies: technically called ATMPs (Advanced Therapy Medicinal Products), ...
-
IU Philanthropic Venture Fund Invests in Regenerative Medicine Company Vascugen
The Indiana University Philanthropic Venture Fund, which provides capital to faculty, students, alumni and staff at all IU campuses to help them further develop their research and innovations into startup companies, has invested in Vascuqen Inc., a regenerative medicine company. Vascugen is focused on finding therapies to repair human tissue damaged by reduced blood flow due to disease or ...
-
World Sepsis Day – Raising awareness about one of the most prevalent and deadly, yet misdiagnosed, medical conditions.
Sepsis is the body’s over active and toxic response to an infection that causes hospitalization of more than 18 million people around the world every year, including 30,000 Canadians Declared a Global Health Priority by the World Health Organization in 2017 80% of sepsis deaths in hospitals could be prevented with rapid diagnosis and treatment Vancouver, Canada: Noting World Sepsis ...
-
CD Formulation Enables Customized Synthesis Service for Osmotic Pressure Regulators for Drug Development
Normal cell function requires the maintenance of osmotic pressure. Therefore, in drug manufacturing, osmotic pressure regulators should be added to the formulation to avoid tissue damage. The US-based CRO company CD Formulation recently announced its ability to synthesize osmotic pressure regulators to suit the needs of different drug projects. These osmotic pressure regulators will help ...
-
Regenerative Medicine Made In Italy
Fortunately, not all brains are fleeing Italy. And when they come together the result is very often of excellence. A striking example is the TMR (registered trademark and acronym of Magnetic Resonance Therapeutic), an innovative medical device that provides great benefits for our health and well-being. The TMR is a 100% Made in Italy device, made by the Thereson company, the result of a long ...
-
Hundreds of lives saved through new technology to spot sepsis
The NHS has saved hundreds of people from sepsis thanks to better use of digital technology in hospitals. In a major nationwide push to tackle the condition, including a one hour identification and treatment ambition, new ‘alert and action’ technology is being introduced which uses algorithms to read patients’ vital signs and alert medics to worsening conditions that are a ...
-
HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics’ Gout Discovery Pipeline
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fifth payment that HemoShear has earned in accordance with the Horizon exclusive ...
-
Chrysalis Biotherapeutics Initiates $5.45 Million Contract With NIH For Nuclear Countermeasure Development
Chrysalis BioTherapeutics, Inc. today announced initiation of a three-year $5.45 million contract with the National Institute of Allergy and Infectious Diseases (NIH-NIAID) to develop TP508 as a countermeasure to increase survival and reduce delayed effects of an accidental or intentional nuclear detonation. “TP508 represents a natural product released at sites of tissue injury to ...
-
Announcement – Total Shoulder Arthroplasty (TSA) Planning Through MRI Scan
RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced AI and computer vision solutions, today announces a new tool for Total Shoulder Arthroplasty (TSA) planning. This tool performs segmentation of the shoulder bones from shoulder MRI scan, which is usually performed in shoulder healthcare. The segmentation output undergoes super-resolution enhancement to ...
By RSIP Vision
-
TIKOMED’S ILB® restores brain energy metabolism following severe traumatic brain injury in the rat demonstrated in data published by the journal Antioxidants
A new study on TIKOMED’s lead drug candidate, ILB®, addressing one of the underlying causes of neurodegeneration in acute and chronic diseases was published in Antioxidants today. The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial effects on the metabolic damages caused by sTBI. “This ...
By TIKOMED AB
-
Vascugen Licenses Stem Cell Technology for Blood Vessel Regeneration Developed at IU School of Medicine
Vascuqen Inc. today announced that it has licensed a suite of intellectual property developed at the Indiana University (IU) School of Medicine related to blood vessel formation from adult stem cells. The regenerative medicine company is focused on finding therapies to repair tissues damaged by reduced blood flow due to disease or injury. The worldwide, exclusive licenses include patent rights ...
-
TX Series added to CoTCCC list of recommended limb tourniquets
RevMedx, Inc., a leader in groundbreaking solutions for the control of severe bleeding, today announced that the CoTCCC has added the TX Series ratcheting tourniquets to its list of recommended Limb Tourniquets. The TX series joins the XSTAT® injectable hemostatic on the TCCC list of recommended hemorrhage control devices for casualty care. Andrew Barofsky, President and CEO of RevMedx, ...
By RevMedx
-
HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fourth payment that HemoShear has earned, following previous payments for the identification and ...
-
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of charitable grants to establish or expand community-focused patient navigator programs. This is the second year of this unique program aimed at eliminating barriers to care for ...
-
Diesel Exhaust + Cholesterol = Cardiovascular Disease
LOS ANGELES, California, July 26, 2007 (ENS) - Exposure to a combination of diesel exhaust and high blood cholesterol increases the risk for heart attack and stroke far more than exposure to either factor alone, new research reveals. The results indicate that controlling air pollution may prove to be a powerful tool for preventing cardiovascular disease. Published in today's edition of the ...
-
Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) will be presented at the 2022 National Kidney Foundation Spring Clinical Meetings, taking place April 6-10, 2022 in Boston, Mass. ...
-
Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001
Stratford-upon-Avon, UK: April, 6 2020 – Celixir, a privately-owned company discovering and developing life-saving advanced therapies, announces an update to its ongoing clinical programme with lead therapeutic candidate CLXR-001. The first patient was successfully dosed in the Company’s Heartcel clinical trial of its novel iMP cells in patients with cardiomyopathy on March 16, 2020 ...
By Celixir plc
-
Accelerating Lupus Drug Discovery & Development - Fireside Chat with Experts in SLE Research
Genuity Science is bringing together a distinguished panel of experts from academia, research and industry to discuss opportunities and advancements in developing better treatments for systemic lupus erythematosus (SLE). SLE is a chronic and relapsing autoimmune disease characterized by a break-down of self-tolerance that leads to tissue inflammation and multiorgan damage. SLE is extremely ...
-
CDRD Launches New Company Developing Life-Saving Sepsis Diagnostic
Marking “World Sepsis Day”, The Centre for Drug Research and Development (CDRD) announces the spin-off of a new company, Sepset Biosciences Inc. The company is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of sepsis – a global healthcare problem that is more common than heart attack and claims ...
-
Accelerate Diagnostics Receives CARB-X Award to Develop Rapid Optical Imaging Technology for Sepsis and Antibiotic-Resistant Infections
CARB-X is awarding Accelerate Diagnostics, a Tucson, Arizona, USA, biotech company, up to US$578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. Accelerate would be eligible for up to $2.1 million in additional funds from CARB-X if the project meets certain milestones, subject to available funds. Sepsis is the body’s overwhelming and life-threatening ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you